Navigation Links
New knowledge about muscular dystrophy
Date:5/5/2014

The most common form of muscular dystrophy among adults is dystrophia myotonica type 1 (DM1), where approximately 1 in every 8000 is affected by the disease. The severity of the disease varies from mild forms to severe congenital forms. It is dominantly inherited and accumulates through generations, gaining increased severity and lowered age of onset. DM1 is characterised by accumulating toxic aggregates of ribonucleic acids (RNA) from a specific mutated gene (see figure 1).

When this RNA, which contains thousands of CUG nucleotide repeats, builds up in the cell, it attracts several cellular proteins, including muscleblind 1 (MBNL1) (see figure 2, left). This binding inhibits the normal function of MBNL1, which means that the cellular level of a number of specific proteins becomes deregulated and the disease develops.

Enzyme characterisation in muscular dystrophy patients

The researchers work at the Department of Molecular Biology and Genetics and the Department of Biomedicine, Aarhus University, where they characterised an enzyme called DDX6, found in both normal cells and cells from muscular dystrophy patients.

The enzyme constantly tries to disperse the toxic aggregates and release MBNL1 in cells from muscular dystrophy patients, which means that the protein can carry out its normal function (see figure 2, right). The enzyme is found in many different cell types, where it performs a number of vital functions. The researchers showed that an artificial increase in the level of DDX6 in muscular dystrophy cells reduces the number of RNA aggregates, while more are formed when DDX6 is removed from the cells.

DDX6 belongs to a class of enzymes called helicases, which can change RNA structure and also regulate the ability of proteins to bind RNA. By purifying DDX6 from human cells, the researchers succeeded in getting the enzyme to bind and carry out an enzymatic reaction outside the cell, thus changing the structure of the toxic RNA.

These results indicate that DDX6 has a direct impact on toxic RNA aggregation in cells from muscular dystrophy patients in addition to its normal functions.

It remains unlikely that DDX6 can be used directly in the treatment of muscular dystrophy, since the enzyme carries out a number of important processes in the cell, which could potentially become deregulated leading to other diseases. However, the results provide important insights into the basic mechanisms of the disease, and natural differences in enzyme levels in different types of cells (or individuals) could possibly explain observed tissue-specific differences in the development of the disease.


'/>"/>

Contact: Christian K. Damgaard
cd@mb.au.dk
45-29-70-05-99
Aarhus University
Source:Eurekalert  

Related medicine news :

1. Pre-test genetic counseling increases cancer knowledge for BRCA patients
2. The Hong Kong Polytechnic University promotes knowledge enterprises through MAKE Award
3. The HearStrong Foundation Launches Nationwide to Acknowledge the Accomplishments of Those with Hearing Loss
4. HeatTechProducts.com to Launch Online Knowledge Center
5. Racial Gap Persists in Womens Heart Health Knowledge: Survey
6. Three Leading Telecommunications and Technology Organizations Sponsor the AG Bell Listening and Spoken Language Knowledge Center
7. Studies advance knowledge of HIV impact on hepatitis C infection and genes that may thwart HCV
8. Passages Malibu Acknowledges the Growing Popularity of “Molly” Among Teens
9. Can Genital Herpes Spread in the Body? polyDNA Surveys the Public Knowledge
10. Its a sure thing: Knowledge of the game is not an advantage in sports gambling
11. Jvion Launches The ICD-10 Knowledge Exchange on Google+
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New knowledge about muscular dystrophy
(Date:8/16/2017)... ... August 16, 2017 , ... Paul Vitenas, MD, FACS , ... Top Doctor. The annual list identifies the nation’s top physicians, in a variety of ... it to the top of Castle Connolly’s coveted ranking. , Castle Connolly is the ...
(Date:8/16/2017)... ... August 16, 2017 , ... SGNA Standards of Infection ... reprocessing cycle, both between patient procedures and before storage, is a requisite practice ... important to the prevention of disease transmission and nosocomial infection as cleaning and ...
(Date:8/16/2017)... ... 16, 2017 , ... Richard Strawn’s new book Surgical ... of a cancer diagnosis, surgery and recovery, the Psalms provided encouragement and hope, ... God shows love to those who are sick., Surgical Psalms contains 36 reflections ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... an opportunity for men and women to train as hospice volunteers. Volunteers provide ... life-limiting illness. For over 30 years, the agency has trained volunteers to be ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... and marketers of high-quality anti-aging skincare solutions, recently announced the launch of two ... are an affordable, yet effective alternative to expensive plastic surgery or in-patient cosmetic ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... OCEANSIDE, Calif. , Aug. 15, 2017  AOTI Inc. announced ... Advanced Oxygen Therapy Inc., has recently opened a New York City ... the ever-increasing usage of its unique Topical Wound Oxygen (TWO 2 ... approved by the Accreditation Commission for Health Care (ACHC) under the ... ...
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 million ... continuing operations Second-quarter 2017 ... million Second-quarter 2017 Sterile ... Second-quarter 2017 adjusted diluted earnings ... to $0.93 Second-quarter 2017 ...
(Date:8/7/2017)... , Aug. 7, 2017  Endo International plc (NASDAQ: ... agreements to resolve virtually all known U.S. mesh product ... to resolve the known remaining U.S. claims at reasonable ... beginning in the fourth quarter of 2017 and continuing ... its second quarter 2017 results, the Company intends to ...
Breaking Medicine Technology: